Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 9Neoplasms by Site 2Neoplasms 2Breast Diseases 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Skin Diseases 1Sarcoma 1Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1HR+/HER2- Breast Cancer 1HER2+ Breast Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Carcinoma, Renal Cell 1Breast Neoplasm Female 1Breast Cancer Recurrent 1Advanced Breast Cancer 1

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2+ Breast Cancer × palbociclib × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡